Registration Study of Acute Ischemic Stroke/Transient Ischemic Attack (TIA) With Atrial Fibrillation

The rate recurrent Ischemic stroke/TIA

Recurrent ischemic stroke/TIA is defined as a new focal neurological deficit of sudden onset lasting at least 24 h (or\<24 h if following therapeutic intervention, i.e. thrombolysis or thrombectomy, or if the deficit results in death\< 24 h), occurring\>24 h after the index ischemic stroke, irrespective of vascular territory and that is not attributable to oedema, brain shift, haemorrhagic transformation, intercurrent illness, hypoxia or drug toxicity;

Time frame: one year

The rate of symptomatic intracranial hemorrhage

Symptomatic intracranial hemorrhage(ICH) is defined as a new focal neurological deficit of sudden onset lasting at least 24 h with documented ICH on imaging (CT orMRI). Any intraparenchymal hematoma (≥ 10 mm) will be considered, including haemorrhagic transformation of the index ischemic stroke. However, microhaemorrhages (\< 10 mm) do not fulfil the study definition of ICH. ICH will be classified as symptomatic if it is associated with≥4 points increase in total National Institutes of Health stroke scale (NIHSS) or≥2 points increase in 1 of the NIHSS categories ;

Time frame: one year

The rate of non-intracranial major hemorrhage

non-intracranial major hemorrhage are those that result in death or are life-threatening as defined by the International Society on Thrombosis and Haemostasis (ISTH) or consume major healthcare resources, which include: - fatal bleeding; and/or - symptomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; and/or - bleeding causing a fall in haemoglobin level of≥ 20 g/L, or leading to transfusion of two or more units of whole blood or red cells; and/or - bleeding events leading to hospitalisation (in addition to the original ISTH definition)

Time frame: one year

the rate of hemorrhagic transformation and the rate of symptomatic hemorrhagic transformation

Hemorrhagic transformation (HT) was defined on CT scan as any degree of hyperdensity within the area of low attenuation and was classified as either hemorrhagic infarction or parenchymal hematoma;symptomatic haemorrhagic transformation of the index ischemic stroke which is associated with≥4 points increase in total National Institutes of Health stroke scale (NIHSS) or≥2 points increase in 1 of the NIHSS categories

Time frame: one month

the rate of vascular death

vascular death is defined as the death caused by vascular events on the basis of which platelet-rich thrombi are formed

Time frame: one year

All cause death

All cause death is defined as the death from various causes

Time frame: one year

the rate of clinically relevant nonmajor bleeding

Clinically relevant nonmajor bleeding is defined as non major bleeding. resulting in hospitalization, medical or surgical intervention, or change, interruption, or discontinuation of the antithrombotic drug

Time frame: one year

Neurological disability

Neurological disability is measured with modified ranking scale (0-5). 0:No symptoms at all; 1:Despite symptoms, it has no obvious dysfunction and can perform all daily duties and activities; 2:Mild disability, unable to complete all pre-illness activities, but without help, can take care of their own affairs;3:Moderate disability requires some help, but walking does not require help; 4:Severe disability, can not walk independently, without the help of others can not meet their own needs; 5:Severe disability, bedridden, incontinence, continuous care and attention are required.

Time frame: one year

the rate of medication persistence with OAC therapy

Medication persistence with OAC therapy is defined as the absence of are fill gap of \>60 days (non-persistence was defined as a gap of \>60 days after the end of the day's supply of the medication of interest). Discontinuation was defined as no additional refill of the medication of interest for \>90 days through to the end of follow-up.

Time frame: one year